InDex Pharmaceuticals Holding AB (publ), a Sweden-based pharmaceutical development company, announced on Wednesday that it has entered into a license agreement with Viatris Pharmaceutical Japan Inc., to register and commercialise cobitolimod in Japan, intended for the treatment of ulcerative colitis.
Cobitolimod, a TLR9 agonist, is being assessed in the global phase III program CONCLUDE, as a novel treatment for moderate to severe ulcerative colitis.
Under the terms of the agreement, Viatris Japan will pay InDex an upfront fee of USD10m for the exclusive rights to commercialise cobitolimod in Japan. In addition, InDex is eligible to receive development and sales milestone payments of up to USD40m. Viatris Japan will also pay up to double-digit percentage royalties based on its net sales for the product in Japan.
InDex will continue to fund all development which incorporates the completion of the global phase III-program CONCLUDE, including a cohort of Japanese patients in Induction Study 2 and a PK study in Japanese patients prior to filing. Viatris Japan will fund all regulatory and commercialization expenses, as well as any additional Japanese-specific studies required in Japan.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration